Compare INNV & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INNV | EYPT |
|---|---|---|
| Founded | 2007 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Nursing Services | Biotechnology: Laboratory Analytical Instruments |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.3B |
| IPO Year | 2021 | 2005 |
| Metric | INNV | EYPT |
|---|---|---|
| Price | $10.79 | $13.66 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $7.00 | ★ $31.80 |
| AVG Volume (30 Days) | 346.4K | ★ 1.1M |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $853,699,000.00 | $7,539,000.00 |
| Revenue This Year | $12.85 | N/A |
| Revenue Next Year | $8.88 | $3,115.57 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 11.76 | N/A |
| 52 Week Low | $3.13 | $8.96 |
| 52 Week High | $10.69 | $19.11 |
| Indicator | INNV | EYPT |
|---|---|---|
| Relative Strength Index (RSI) | 80.18 | 54.50 |
| Support Level | $7.33 | $13.61 |
| Resistance Level | $10.69 | $14.82 |
| Average True Range (ATR) | 0.53 | 0.80 |
| MACD | 0.20 | 0.18 |
| Stochastic Oscillator | 90.90 | 64.85 |
InnovAge Holding Corp is a healthcare delivery platform comprising multiple participants focused on providing all-inclusive, capitated care to high-cost seniors, many of whom are dual-eligible. Its programs are designed to address two of the pressing challenges facing the U.S. healthcare industry: rising costs and poor outcomes. The purpose of the participant-centered care delivery approach is to improve the quality of care participants receive, while keeping them in their homes for as long as possible and reducing the overutilization of high-cost care settings, such as hospitals and nursing homes. The company manages its business as one reportable segment, PACE.
EyePoint Inc focuses is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained-release product candidate for retinal diseases, with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.